UP FRONT MATTERSPTH-Related Peptide (PTHrP) in HypercalcemiaMundy, Gregory R.; Edwards, James R. Author Information Vanderbilt Center for Bone Biology, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University, Nashville, Tennessee Correspondence: Dr. Gregory R Mundy, Vanderbilt Center for Bone Biology, 1235 Medical Research Building IV, Nashville, TN 37232-0575. Phone: 615-322-6110; Fax: 615-343-2611; E-mail: [email protected] Journal of the American Society of Nephrology 19(4):p 672-675, April 2008. | DOI: 10.1681/ASN.2007090981 Buy Metrics Abstract It is now 20 years since the tumor-associated factor parathyroid hormone–related peptide was identified. Since then, there have been significant changes in the understanding of the hypercalcemic syndromes associated with malignancy and with the role of this peptide in normal physiology as well as this specialized pathologic setting. Parathyroid hormone–related peptide has become a useful diagnostic tool in the differential diagnosis of hypercalcemia, and approaches to inhibit its expression or its effects by malignant cells hold promise for treating the hypercalcemia and osteolysis associated with some cancers. Copyright © 2008 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.